Newsfeeds - Spark Newswire

2 minute read

GlycoMimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan In Patients With Relapsed /Refractory Acute Myeloid Leukemia

Today, 9:05 PM

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML. A

GLYC

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 12, 2021

By Benzinga Insights

Today, 9:05 PM

AFIB

2 minute read

18 Stocks Moving In Friday’s Pre-Market Session

By Lisa Levin

Today, 9:05 PM

Gainers NuZee, Inc. (NASDAQ: NUZE) rose 30.3% to $6.89 in pre-market trading after jumping around 165% on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart stores nationwide.

AVGR

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 9:05 PM

ALDX

19 minute read

Earnings Scheduled For November 2, 2021

By Benzinga Insights

Today, 9:05 PM

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

1 minute read

FDA
News

Lena Napolitano-Sponsored Study Titled ‘Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia’ Posted To ClinicalTrails.Gov; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 9:05 PM

https://clinicaltrials.gov/ct2/show/NCT05057221

GLYC

1 minute read

GlycoMimetics’ Lead Candidate Data Published In An Online Journal

By Vandana Singh

Today, 9:05 PM

GlycoMimetics Inc (NASDAQ:GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online…

GLYC

2 minute read

News

Efficacy And Safety Data For GlycoMimetics’ Lead Investigational Drug Uproleselan Published In BLOOD

By Benzinga Newsdesk

Today, 9:05 PM

Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics' lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists

GLYC